Rebecca Araujo

DocwireNews

Post-transplant cyclophosphamide with tacrolimus and mycophenolate (PTCy/Tac/MMF) and tacrolimus plus methotrexate (Tac-MTX) provided similar rates of graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplant (HSCT) with myeloablative conditioning, according to results of a retrospective study presented at the <a href="https://www.hoparx.org/hopa-learn/conferences-events/" target="_blank" rel="noopener">Hematology/Oncology Pharmacy Association Annual Conference 2024</a>.Adult patients who underwent HSCT with a human leukocyte antigen (HLA)-matched related donor (MRD) or an HLA-matched unrelated donor (MUD) at a single center were included. The primary outcome was GVHD-free, relapse-free survival (GRFS) at 1 year. Seventy-seven patients received a regimen of Tac-MTX and 13 patients received PTCy/Tac/MMF.At 1 year, the rate of GRFS was 6.5% (95% CI, 1-12) in the Tac-MTX group and 21.0% (95% CI, 0-44) in the PTCy/Tac/MMF group (P=.066). In the Tac-MTX group, the rate of acute GVHD at any grade was 68.8% and at grade 3-4 was 7.8%; the rate of any chronic GVHD was 54.5% and moderate to severe chronic GVHD was 45.5%. In the PTCy/Tac/MMF group, 30.8% of patients developed acute GVHD and no patients developed grade 3-4 acute GVHD; 38.5% developed chronic GVHD overall and 23.1% developed moderate to severe GVHD. Median days to neutrophil engraftment was 18.0 days in the Tac-MTX group and 17.5 days in the PTCy/Tac/MMF group. The rate of 1-year relapse was 13% in the Tac-MTX group and 15% in the PTCy/Tac/MMF group; 1-year overall survival was 70% and 68%, respectively.In summary, &ldquo;PTCy/Tac/MMF and Tac-MTX did not significantly differ in regard to 1-year GRFS among those who received an HSCT from an MRD or MUD following myeloablative conditioning,&rdquo; the authors wrote. They noted that the study is limited by the small PTCy/Tac/MMF group and the short follow-up period.<h4>Reference</h4>Cash MC, Eberwein EM, Eubanks ER, Schrum DP, Burrows J, Lee HJ. Post-transplant cyclophosphamide, tacrolimus, and mycophenolate vs. tacrolimus and methotrexate as graft-versus-host disease prevention following allogeneic stem cell transplant with myeloablative conditioning. Poster. Presented at the Hematology/Oncology Pharmacy Association Annual Conference 2024; April 3-6, 2024; Tampa, Florida.

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Study Compares PTCy/Tac/MMF, Tacrolimus Plus Methotrexate to Prevent GVHD After HSCT

HOPA Annual Conference 2024

Post-transplant cyclophosphamide with tacrolimus and mycophenolate and tacrolimus plus methotrexate provided similar rates of graft-versus-host disease prevention after allogeneic 

PTCy/Tac/MMF, Tacrolimus Plus Methotrexate Offer Similar Protection Against GVHD After HSCT

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe